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To date severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 37 
100 million individuals resulting in over two million deaths. Many vaccines are being 38 
deployed to prevent coronavirus disease 2019 (COVID-19) including two novel mRNA-39 
based vaccines1,2. These vaccines elicit neutralizing antibodies and appear to be safe and 40 
effective, but the precise nature of the elicited antibodies is not known3-6. Here we report on 41 
the antibody and memory B cell responses in a cohort of 20 volunteers who received either 42 
the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines. Consistent with 43 
prior reports, 8 weeks after the second vaccine injection volunteers showed high levels of 44 
IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) 45 
binding titers3,5,6. Moreover, the plasma neutralizing activity, and the relative numbers of 46 
RBD-specific memory B cells were equivalent to individuals who recovered from natural 47 
infection7,8. However, activity against SARS-CoV-2 variants encoding E484K or N501Y or 48 
the K417N:E484K:N501Y combination was reduced by a small but significant margin.  49 
Consistent with these findings, vaccine-elicited monoclonal antibodies (mAbs) potently 50 
neutralize SARS-CoV-2, targeting a number of different RBD epitopes in common with 51 
mAbs isolated from infected donors. Structural analyses of mAbs complexed with S trimer 52 
suggest that vaccine- and virus-encoded S adopts similar conformations to induce 53 
equivalent anti-RBD antibodies. However, neutralization by 14 of the 17 most potent mAbs 54 
tested was reduced or abolished by either K417N, or E484K, or N501Y mutations. Notably, 55 
the same mutations were selected when recombinant vesicular stomatitis virus 56 
(rVSV)/SARS-CoV-2 S was cultured in the presence of the vaccine elicited mAbs. Taken 57 
together the results suggest that the monoclonal antibodies in clinical use should be tested 58 
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against newly arising variants, and that mRNA vaccines may need to be updated 59 
periodically to avoid potential loss of clinical efficacy.   60 
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Between 19 October 2020 and 15 January 2021, 20 volunteers who received two doses of the 61 
Moderna (n=14) or Pfizer-BioNTech mRNA (n=6) vaccines were recruited for blood donation 62 
and analyzed. Ages of the analyzed volunteers ranged from 29-69 years (median 43); 12 63 
(60%) were male and 8 (40%) female. 16 participants identified as Caucasian, 2 as Hispanic, and 64 
1 as African American or Asian, respectively. The time from the second vaccination to sample 65 
collection varied between 3-14 weeks with an average of 8 weeks. None of the volunteers had a 66 
history of prior SARS-CoV-2 infection and none experienced serious adverse events after 67 
vaccination (Extended Data Table 1).  68 
 69 
Vaccine plasma binding and neutralizing activity against SARS-CoV-2 70 
Plasma IgM, IgG and IgA responses to SARS-CoV-2 S and RBD were measured by enzyme-71 
linked immunosorbent assay (ELISA)7,8. All individuals tested showed reactivity to S and RBD 72 
that was significantly higher compared to pre-COVID-19 historic controls (Extended Data Fig 73 
1a-f). As might be expected anti-S and -RBD IgG levels were higher than IgM or IgA. 74 
Moreover, there was a strong positive correlation between anti-RBD and anti-S response in all 75 
three immunoglobulin isotypes measured (Extended Data Fig 1g-i). In line with previous 76 
reports3,6,9, IgG and IgM levels were significantly higher in the vaccinated group compared to a 77 
cohort of convalescent patients assayed 1.3 and 6.2 months after infection, while IgA levels were 78 
similar (Extended Data Fig 1j-l).  79 
 80 
Plasma neutralizing activity was determined using human immunodeficiency virus-1 (HIV-1) 81 
pseudotyped with SARS-CoV-2 S protein7,8,10. In agreement with previous reports3,6,9, there was 82 
a broad range of plasma neutralizing activity 3-14 weeks after the second vaccine dose that was 83 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted January 30, 2021. ; https://doi.org/10.1101/2021.01.15.426911doi: bioRxiv preprint 
 6 
similar to that elicited by natural infection in a convalescent cohort after 1.3 months, and greater 84 
than the activity at 6.2 months after infection (Fig. 1a, Extended Data Table 1). There was no 85 
significant difference in neutralizing activity between the Moderna and Pfizer-BioNTech 86 
vaccines (Fig. 1b). Whereas convalescent antibody titers tend to correlate with severity and 87 
length of time of infection, additional sampling would be required to understand the correlates of 88 
the magnitude of the vaccine responses. As expected, plasma neutralizing activity was directly 89 
correlated to anti-S and -RBD binding titers in ELISAs7,8 (Fig. 1c, d, and Extended Data Fig. 2a-90 
d). Finally, RBD and S binding, and neutralizing activities were directly correlated to the time 91 
between the first vaccine dose and blood donation with significantly reduced levels in all 3 92 
measurements with time (Fig. 1e, f and g, and Extended Data Fig. 2e-h)11. However, this and 93 
other small studies3,11 cannot accurately predict the half-life of the neutralizing response. Larger 94 
numbers of individuals in diverse cohorts will need to be studied to determine the precise half-95 
life of the vaccine elicited neutralizing response. 96 
 97 
To determine whether plasma from vaccinated individuals can neutralize circulating SARS-CoV-98 
2 variants of concern and mutants that arise in vitro under antibody pressure 12,13, we tested 99 
vaccinee plasma against a panel of 10 mutant pseudotype viruses including recently reported 100 
N501Y (B1.1.7 variant), K417N, E484K and the combination of these 3 RBD mutations 101 
(501Y.V2 variant)14-19. Vaccinee plasma was significantly less effective in neutralizing the HIV-102 
1 virus pseudotyped with certain SARS-CoV-2 mutant S proteins (Fig. 1h and i and Extended 103 
Data Fig. 2j). Among the volunteer plasmas tested there was a 1- to 3-fold decrease in 104 
neutralizing activity against E484K, N501Y and the K417N:E484K:N501Y combination  (p= 105 
0.0033, p=0.0002, and p<0.0001, respectively, Fig. 1h and i). Similarly, convalescent plasma 106 
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obtained 1.3 and 6.2 months after infection was 0.5- to 29- and 0.5- to 20.2-fold less effective in 107 
neutralizing the K417N:E484K:N501Y combination (p=0.001 and p<0.0001, respectively, Fig. 108 
1j, Extended Data Table 2). We conclude that the plasma neutralizing activity elicited by either 109 
mRNA vaccination or natural infection is variably but significantly less effective against 110 
pseudoviruses that carry RBD mutations found in emerging SARS-CoV-2 variants. 111 
   112 
Vaccine-elicited SARS-CoV-2 RBD-specific monoclonal antibodies 113 
Although circulating antibodies derived from plasma cells wane over time, long-lived immune 114 
memory can persist in expanded clones of memory B cells7,20. We used flow cytometry to 115 
enumerate the circulating SARS-CoV-2 RBD-specific memory B cells elicited by mRNA 116 
immunization7,8 (Fig. 2a, Extended Data Fig. 3a and b). We focused on the RBD since it is the 117 
target of the majority of the more potent SARS-CoV-2 neutralizing antibodies discovered to 118 
date21-26. Notably, the percentage of RBD-binding memory B cells in vaccinees was significantly 119 
greater than in naturally infected individuals assayed after 1.3 months, but similar to the same 120 
individuals assayed after 6.2 months (Fig. 2b). The percentage of RBD-binding memory B cells 121 
in vaccinees was not correlated to the time after vaccination (Extended Data Fig. 3c). Thus, 122 
mRNA vaccination elicits a robust SARS-CoV-2 RBD-specific B cell memory response that 123 
resembles natural infection.  124 
 125 
To examine the nature of the antibodies produced by memory B cells in response to vaccination, 126 
we obtained 1,409 paired antibody heavy and light chains from RBD binding single B cells from 127 
14 individuals (n=10 Moderna and n=4 Pfizer-BioNTech vaccinees) (Extended Data Table 3). 128 
Expanded clones of cells comprised 4-50% of the overall RBD binding memory B cell 129 
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compartment (Fig. 2c and d, and Extended Data Fig. 3d).  Similar to natural infection, IGVH 3-130 
53, and 3-30 and some IGVL genes were significantly over-represented in the RBD-binding 131 
memory B cell compartment of vaccinated individuals (Fig. 2e, Extended Data Fig. 4a). In 132 
addition, antibodies that share the same combination of IGHV and IGLV genes in vaccinees 133 
comprised 39% of all the clonal sequences (Extended Data Fig. 4b) and 59% when combined 134 
with naturally infected individuals7,8 (Fig. 2f), and some of these antibodies were nearly identical 135 
(Extended Data Table 3 and 4). The number of V gene nucleotide mutations in vaccinees is 136 
greater than in naturally infected individuals assayed after 1.3 months, but lower than that in the 137 
same individuals assayed after 6.2 months (Fig. 2g and Extended Data Fig. 5a). The length of the 138 
IgH CDR3 was similar in both natural infected individuals and vaccinees and hydrophobicity 139 
was below average27 (Fig. 2h and Extended Data Fig. 5a and b). Thus, the IgG memory response 140 
is similar in individuals receiving the Pfizer-BioNTech and Moderna vaccines and both are rich 141 
in recurrent and clonally expanded antibody sequences.  142 
 143 
One hundred and twenty-seven representative antibodies from 8 individuals were expressed and 144 
tested for reactivity to the RBD (Extended Data Table 5). The antibodies included: (1) 76 that 145 
were randomly selected from those that appeared only once, and (2) 51 representatives of 146 
expanded clones. Of the antibodies tested 98% (124 out of the 127) bound to RBD indicating 147 
that single cell sorting by flow cytometry efficiently identified B cells producing anti-RBD 148 
antibodies (Extended Data Fig. 6a-c and Table 5). In anti-RBD ELISAs the mean half-maximal 149 
effective concentration (EC50) was higher than that observed in infected individuals after 6.2 150 
months but not significantly different from antibodies obtained 1.3 months after infection 151 
(Extended Data Fig. 6a, and Table 5 and 7,8). To examine memory B cell antibodies for binding 152 
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to circulating SARS-CoV-2 variants and antibody resistant mutants we performed ELISAs using 153 
mutant RBDs12,15,28-31. Twenty-two (26%) of the 84 antibodies tested showed at least 5-fold 154 
decreased binding to at least one of the mutant RBDs (Extended data Fig. 6d-n and Table 5).  155 
 156 
SARS-CoV-2 S pseudotyped viruses were used to measure the neutralizing activity of all 127 157 
antibodies7,8,10 (Fig. 3a, Extended Data Table 5). Consistent with the plasma neutralization 158 
results, the geometric mean neutralization half-maximal inhibitory concentration of the Pfizer-159 
BioNTech and Moderna vaccinee antibodies were not significantly different from each other or 160 
to antibody collections obtained from naturally infected individuals 1.3 or 6.2 months after 161 
infection (Fig. 3a and 7,8).  162 
 163 
To examine the neutralizing breadth of the monoclonal antibodies and begin to map their target 164 
epitopes we tested 17 of the most potent antibodies (Extended data Table 6), 8 of which carried 165 
IgHV3-53, against a panel of 12 SARS-CoV-2 variants: A475V is resistant to class 1 antibodies 166 
(structurally defined as described29); E484K and Q493R are resistant to class 2 167 
antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 168 
antibodies7,8,12,13,29,33. Additionally, K417N, Y453F, S477R, N501Y, and D614G represent 169 
circulating variants some of which have been associated with rapidly increasing case 170 
numbers14,15,19,33-35. Based on their neutralizing activity against the variants, all but 3 of the 171 
antibodies were provisionally assigned to a defined antibody class or a combination (Fig. 3b). As 172 
seen in natural infection, a majority of the antibodies tested (9/17) were at least ten-fold less 173 
effective against pseudotyped viruses carrying the E484K mutation7,12,29. In addition, 5 of the 174 
antibodies were less potent against K417N and 4 against N501Y by ten-fold or more (Fig. 3b). 175 
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Similar results were obtained with antibodies being developed for clinical use (REGN10987, 176 
REGN10933, COV2-2196, COV2-2130, C135 and C144 (Extended data Fig. 7)). However, 177 
antibody combinations remained effective against all of the variants tested confirming the 178 
importance of using antibody combinations in the clinic (Extended data Fig. 7). Whether less 179 
potent antibodies show similar degrees of sensitivity to these mutations remains to be 180 
determined.  181 
 182 
To determine whether antibody-imposed selection pressure could also drive the emergence of 183 
resistance mutations in vitro, we cultured an rVSV/SARS-CoV-2 recombinant virus in the 184 
presence of each of 18 neutralizing monoclonal antibodies. All of the tested antibodies selected 185 
for RBD mutations. Moreover, in all cases the selected mutations corresponded to residues in the 186 
binding sites of their presumptive antibody class (Fig. 3b and c). For example, antibody C627, 187 
which was assigned to class 2 based on sensitivity to the E484K mutation, selected for the 188 
emergence of the E484K mutation in vitro (Fig 3c). Notably, 6 of the antibodies selected for 189 
K417N, E or T, 5 selected for E484K and 3 selected for N501Y, T or H, which coincide with 190 
mutations present in the circulating B.1.1.17/501Y.V1, B.1.351/501Y.V2 and B1.1.28/501.V3 191 
(P.1) variants that have been associated with rapidly increasing case numbers in particular 192 
locales14,17,18,36.   193 
 194 
Cryo-EM Mapping of Antibody Epitopes 195 
To further characterize antibody epitopes and mechanisms of neutralization, we characterized 196 
seven complexes between mAb Fab fragments and the prefusion, stabilized ectodomain trimer of 197 
SARS-CoV-2 S glycoprotein37 using single-particle cryo-EM (Fig 4 and Extended Data Table 7). 198 
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Overall resolutions ranged from 5-8 Å (Extended Data Fig. 8) and coordinates from S trimer and 199 
representative Fab crystal structures were fit by rigid body docking into the cryo-EM density 200 
maps to provide a general assessment of antibody footprints/RBD epitopes.  Fab-S complexes 201 
exhibited multiple RBD-binding orientations recognizing either ‘up’/’down’ (Fig 4a-j) or solely 202 
‘up’ (Fig 4k-n) RBD conformations, consistent with structurally defined antibody classes from 203 
natural infection (Fig 4o)29. The majority of mAbs characterized (6 of 7) recognized epitopes that 204 
included RBD residues involved in ACE2 recognition, suggesting a neutralization mechanism 205 
that directly blocks ACE2-RBD interactions. Additionally, structurally defined antibody epitopes 206 
were consistent with RBD positions that were selected in rVSV/SARS-CoV-2 recombinant virus 207 
outgrowth experiments, including residues K417, N439/N440, E484, and N501 (Fig 3c and Fig 208 
4f-j,m,n). Taken together, these data suggest that functionally similar antibodies are raised during 209 
vaccination and natural infection, and that the RBDs of spike trimers translated from the mRNA 210 
delivered by vaccination adopt both ‘up’ and ’down’ conformations as observed on structures of 211 
trimer ectodomains29 and trimers on the surface of SARS-CoV-2 virions38. 212 
 213 
Discussion 214 
The mRNA-based SARS-CoV-2 vaccines are safe and effective and being deployed globally to 215 
prevent infection and disease. The vaccines elicit antibody responses against the RBD, the major 216 
target of neutralizing antibodies21-26, in a manner that resembles natural infection. Notably, the 217 
neutralizing antibodies produced by mRNA vaccination target the same epitopes as natural 218 
infection. The data are consistent with SARS-CoV-2 spike trimers translated from the injected 219 
RNA adopting a range of different conformations. Moreover, different individuals immunized 220 
with either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines produce 221 
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closely related and nearly identical antibodies. Whether or not neutralizing antibodies to epitopes 222 
other that RBD are elicited by vaccination remains to be determined.  223 
 224 
Human neutralizing monoclonal antibodies to the SARS-CoV-2 RBD can be categorized as 225 
belonging to 4 different classes based on their target regions on the RBD29. Class 1 and 2 226 
antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39. These 227 
antibodies target epitopes that overlap or are closely associated with RBD residues K417, E484 228 
and N501. They are frequently sensitive to mutation in these residues and select for K417N, 229 
E484K and N501Y mutations in SARS-CoV-2 S protein expression libraries in yeast and VSV 230 
12,15,33. To avert selection and escape, antibody therapies should be composed of combinations of 231 
antibodies that target non-overlapping or highly conserved epitopes8,12,13,33,40-44.  232 
  233 
A number of circulating SARS-CoV-2 variants that have been associated with rapidly increasing 234 
case numbers and have particular prevalence in the UK (B.1.1.7/501Y.V1), South Africa 235 
(B.1.351/501Y.V2) and Brazil (P.1)14,17,18,36. Our experiments indicate that the RBD mutations 236 
found in these variants, and potentially others that carry K417N/T, E484K and N501Y 237 
mutations, can reduce the neutralization potency of vaccinee and convalescent plasma against 238 
SARS-CoV-2 pseudotyped viruses. Although our assays are limited to pseudotyped viruses there 239 
is an excellent correlation between pseudotyped and authentic SARS-CoV-2 neutralization 240 
assays10. In addition, similar results have been reported by others using vaccinee and 241 
convalescent plasmas and a variety of different pseudotype and authentic virus assays15,31,45-49. 242 
 243 
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The comparatively modest effects of the mutations on viral sensitivity to plasma reflects the 244 
polyclonal nature of the neutralizing antibodies in vaccinee plasma. Nevertheless, emergence of 245 
these particular variants is consistent with the dominance of the class 1 and 2 antibody response 246 
in infected or vaccinated individuals. We speculate that these mutations emerged in response to 247 
immune selection in individuals with non-sterilizing immunity. What the long-term effect of 248 
accumulation of mutations on the SARS-CoV-2 pandemic will be is not known, but the common 249 
cold coronavirus HCoV-229E evolves antigenic variants that are comparatively resistant to the 250 
older sera but remain sensitive to contemporaneous sera50. Thus, it is possible that these 251 
mutations and others that emerge in individuals with suboptimal or waning immunity will erode 252 
the effectiveness of natural and vaccine elicited immunity. The data suggests that SARS-CoV-2 253 
vaccines and antibody therapies may need to be updated and immunity monitored in order to 254 
compensate for viral evolution. 255 
  256 
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Figure Legends 257 
Fig. 1. Plasma neutralizing activity.  258 
a, SARS-CoV-2 pseudovirus neutralization assay. NT50 values for COVID-19 convalescent 259 
plasma measured at 1.3 months8 and 6.2 months7 after infection as well as plasma from 260 
vaccinees. NT50 values lower than 10 were plotted at 10. Mean of 2 independent experiments. 261 
Red bars and indicated values represent geometric mean NT50 values. Statistical significance was 262 
determined using the two-tailed Mann-Whitney U-test. Pre-COVID-19 historical control plasma 263 
was analyzed as a negative control and showed no detectable neutralization (NT50<10). b, NT50 264 
values for Moderna mRNA-1273 (black) and Pfizer-BioNTech BNT162b2 (red) vaccine 265 
recipients. Red bars and indicated values represent geometric mean NT50 values. Statistical 266 
significance was determined using the two-tailed Mann-Whitney U-test.  c, Anti-RBD IgG AUC 267 
(Y axis) plotted against NT50 (X axis) r=0.82, p<0.0001. d, Anti-S IgG AUC (Y axis) plotted 268 
against NT50 (X axis) r=0.83, p<0.0001. e, Anti-RBD IgG AUC (Y axis) plotted against time 269 
between first dose and blood draw (X axis) r=-0.59 p=0.0058. f, Anti-S IgG AUC (Y axis) 270 
plotted against time between first dose and blood draw (X axis) r=-0.62 p=0.0038. g, NT50 (Y 271 
axis) plotted against time between first dose and blood draw (X axis) r=-0.69 p=0.0008. The r 272 
and p values for correlations in c-g were determined by two-tailed Spearman correlation. 273 
Moderna vaccinees are in black and Pfizer-BioNTech in red. h. Examples of neutralization 274 
assays, comparing the sensitivity of pseudotyped viruses with WT and RBD mutant SARS-CoV-275 
2 S proteins to vaccinee plasma. MOD1 and PFZ10 indicate two representative individuals 276 
receiving the Moderna and Pfizer-BioNTech vaccine, respectively (for details see Ext. Data 277 
Table 1). i, NT50 values for vaccinee plasma (n=15) neutralization of pseudotyped viruses with 278 
WT and the indicated RBD-mutant SARS-CoV-2 S proteins. Pfizer-BioNTech vaccinees in red. 279 
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j, NT50 values for convalescent plasma (n=45) neutralization of pseudotyped viruses with WT 280 
and KEN (K417N/E484K/N501Y) SARS-CoV-2 S proteins. Statistical significance in i and j 281 
was determined using one tailed t-test. All experiments were performed a minimum of 2 times. 282 
Pseutotyped viruses containing the E484K mutation and corresponding WT controls contain the 283 
R683G mutation (for details see methods). 284 
 285 
Fig. 2. Memory B cell antibodies.  286 
a, Representative flow cytometry plots showing dual AlexaFluor-647-RBD and PE-RBD binding 287 
B cells for 4 vaccinees. b, as in a, dot plot summarizes the percentage of RBD binding B cells in 288 
19 vaccinees, in comparison to a cohort of infected individuals assayed 1.3 and 6.2 months after 289 
infection7,8. Individuals who received the Moderna vaccine are shown in black and Pfizer-290 
BioNTech vaccine recipients in red. Red horizontal bars indicate mean values. Statistical 291 
significance was determined using two-tailed Mann–Whitney U-tests. c, Pie charts show the 292 
distribution of antibody sequences from the 4 individuals in a. The number in the inner circle 293 
indicates the number of sequences analyzed. Pie slice size is proportional to the number of 294 
clonally related sequences. The black outline indicates the frequency of clonally expanded 295 
sequences. d, as in c, graph shows relative clonality among 14 vaccinees assayed, individuals 296 
who received the Moderna vaccine are shown in black and Pfizer-BioNTech vaccine recipients 297 
in red. Red horizontal bars indicate mean values. Statistical significance was determined using 298 
two-tailed Mann–Whitney U-tests. e, Graph shows relative abundance of human IGVH genes 299 
Sequence Read Archive accession SRP010970 (orange), and vaccinees (blue). A two-sided 300 
binomial test was used to compare the frequency distributions, significant differences are 301 
denoted with stars (* p < 0.05, ** p < 0.01, *** p < 0.001, **** = p < 0.0001). f, Clonal 302 
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relationships between sequences from 14 vaccinated individuals (Moderna in black, Pfizer-303 
BioNTech in red Extended Data Table 3) and naturally infected individuals (in green, from7,8). 304 
Interconnecting lines indicate the relationship between antibodies that share V and J gene 305 
segment sequences at both IGH and IGL. Purple, green and grey lines connect related clones, 306 
clones and singles, and singles to each other, respectively. g, Number of somatic nucleotide 307 
mutations in the IGVH (top) and IGVL (bottom) in vaccinee antibodies (Extended Data Table 3) 308 
compared to natural infection obtained 1.3 or 6.2 months after infection7,8. Statistical 309 
significance was determined using the two-tailed Mann–Whitney U-tests and red horizontal bars 310 
indicate mean values. h, as in g, but for CDR3 length.  311 
  312 
Fig. 3: Anti-SARS-CoV-2 RBD monoclonal antibody neutralizing activity.  313 
a, SARS-CoV-2 pseudovirus neutralization assay. IC50 values for antibodies cloned from 314 
COVID-19 convalescent patients measured at 1.3 and 6.2 months7,8 after infection as well as 315 
antibodies cloned from Moderna mRNA-1273 (black) and Pfizer-BioNTech BNT162b2 (red) 316 
mRNA- vaccine recipients. Antibodies with IC50 values above 1000 ng/ml were plotted at 1000 317 
ng/ml. Mean of 2 independent experiments. Red bars and indicated values represent geometric 318 
mean IC50 values in ng/ml. Statistical significance was determined using the two-tailed Mann-319 
Whitney U-test. Isotype control antibody was analyzed in parallel and showed no detectable 320 
neutralization. b, IC50 values for 17 selected mAbs for neutralization of wild type and the 321 
indicated mutant SARS-CoV-2 pseudoviruses. Color gradient indicates IC50 values ranging from 322 
0 (white) to 1000 ng/ml (red). c, Antibody selection pressure can drive emergence of S variants 323 
in cell culture; the percentage of sequence reads encoding the indicated RBD mutations after a 324 
single passage of rVSV/SARS-CoV-2 in the presence of the indicated antibodies is tabulated. 325 
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Color gradient indicates percentage of sequence reads bearing the indicated mutation ranging 326 
from 0 (white) to 100 (red). Positions for which no sequence read was detected are shown in 327 
grey. The percentages calculated for a given position are based on all the reads, and not just the 328 
reads that include that position. K417N, E484K/R683G and N501 are highlighted in b and c as 329 
they constitute important circulating variants. 330 
 331 
Fig. 4. Cryo-EM reconstructions of Fab-S complexes.  332 
Cryo-EM densities for Fab-S complexes (a-e; k-l) and close-up views of antibody footprints on 333 
RBDs (f-j; m-n) are shown for neutralizing mAbs. As expected, due to Fab inter-domain 334 
flexibility, cryo-EM densities (a-e; k-l) were weak for the Fab CH-CL domains. Models of 335 
antibody footprints on RBDs (f-j; m-n) are presented as Fab VH-VL domains (cartoon) 336 
complexed with the RBD (surface). To generate models, coordinates of stabilized S trimer (PDB 337 
6XKL) and representative Fab fragments (PDB 6XCA or 7K8P) with CDR3 loops removed were 338 
fit by rigid body docking into the cryo-EM density maps. a,f, C669; b,g, C643; c,h, C603; d,i, 339 
C601; e,j, C670; k,m, C666; and l,n, C663. RBD residues K417, N439, N440, E484, and N501 340 
are highlighted as red surfaces. The N343 glycan is shown as a teal sphere. o, Composite model 341 
illustrating targeted epitopes of RBD-specific neutralizing mAbs (shown as VH-VL domains in 342 
colors from panels a-l) elicited from mRNA vaccines.  343 
  344 
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 345 
Data reporting  346 
No statistical methods were used to predetermine sample size. The experiments were not 347 
randomized and the investigators were not blinded to allocation during experiments and outcome 348 
assessment.  349 
 350 
Study participants.  351 
To isolate and characterize anti-SARS-CoV-2 RBD antibodies from vaccinees, a cohort 352 
of 20 individuals that participated in either the Moderna or Pfizer-BioNTech phase 3 vaccine 353 
clinical trials and did not report prior history of SARS-CoV-2 infection was recruited at the NIH 354 
Blood Center and the Rockefeller University Hospital for blood donation. Eligible participants 355 
included adults, at least 18 years of age with no known heart, lung, kidney disease or bleeding 356 
disorders, no history of HIV-1 or malaria infection. All participants were asymptomatic at the 357 
time of the study visit and had received a complete 2 dose regimen of either mRNA vaccine. 358 
Informed consent was obtained from all participants and the study was conducted in accordance 359 
with Good Clinical Practice. The study visits and blood draws were reviewed and approved 360 
under the National Institutes of Health’s Federalwide Assurance (FWA00005897), in accordance 361 
with Federal regulations 45 CFR 46 and 21 CFR 5 by the NIH Intramural Research Program IRB 362 
committee (IRB# 99CC0168, Collection and Distribution of Blood Components from Healthy 363 
Donors for In Vitro Research Use) and by the Institutional Review Board of the Rockefeller 364 
University (IRB# DRO-1006, Peripheral Blood of Coronavirus Survivors to Identify Virus-365 
Neutralizing Antibodies). For detailed participant characteristics see Extended Data Table 1. 366 
 367 
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Blood samples processing and storage.  368 
Samples collected at NIH were drawn from participants at the study visit and processed within 369 
24 hours. Briefly, whole blood samples were subjected to Ficoll gradient centrifugation after 1:1 370 
dilution in PBS. Plasma and PBMC samples were obtained through phase separation of plasma 371 
layer and Buffy coat phase, respectively. PBMCs were further prepared through centrifugation, 372 
red blood cells lysis and washing steps, and stored in CellBanker cell freezing media 373 
(Amsbio). All samples were aliquoted and stored at - 80 °C and shipped on dry ice. Prior to 374 
experiments, aliquots of plasma samples were heat-inactivated (56°C for 1 hour) and then stored 375 
at 4°C. Peripheral Blood Mononuclear Cells (PBMCs) obtained from samples collected at 376 
Rockefeller University were purified as previously reported7,8 by gradient centrifugation and 377 
stored in liquid nitrogen in the presence of FCS and DMSO. Heparinized plasma samples were 378 
aliquoted and stored at -20°C or less. Prior to experiments, aliquots of plasma samples were heat-379 
inactivated (56°C for 1 hour) and then stored at 4°C. 380 
 381 
ELISAs  382 
ELISAs51,52 to evaluate antibodies binding to SARS-CoV-2 S (BioHub), RBD and additional 383 
mutated RBDs were performed by coating of high-binding 96-half-well plates (Corning 3690) 384 
with 50 μl per well of a 1μg/ml protein solution in PBS overnight at 4 °C. Plates were washed 6 385 
times with washing buffer (1× PBS with 0.05% Tween-20 (Sigma-Aldrich)) and incubated with 386 
170 μl per well blocking buffer (1× PBS with 2% BSA and 0.05% Tween-20 (Sigma)) for 1 h at 387 
room temperature. Immediately after blocking, monoclonal antibodies or plasma samples were 388 
added in PBS and incubated for 1 h at room temperature. Plasma samples were assayed at a 389 
1:66.6 (RU samples) or a 1:33.3 (NIH samples) starting dilution and 7 additional threefold serial 390 
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dilutions. Monoclonal antibodies were tested at 10 μg/ml starting concentration and 10 additional 391 
fourfold serial dilutions. Plates were washed 6 times with washing buffer and then incubated 392 
with anti-human IgG, IgM or IgA secondary antibody conjugated to horseradish peroxidase 393 
(HRP) (Jackson Immuno Research 109-036-088 109-035-129 and Sigma A0295) in blocking 394 
buffer at a 1:5,000 dilution (IgM and IgG) or 1:3,000 dilution (IgA). Plates were developed by 395 
addition of the HRP substrate, TMB (ThermoFisher) for 10 min (plasma samples) or 4 minutes 396 
(monoclonal antibodies), then the developing reaction was stopped by adding 50 μl 1 M H2SO4 397 
and absorbance was measured at 450 nm with an ELISA microplate reader (FluoStar Omega, 398 
BMG Labtech) with Omega and Omega MARS software for analysis. For plasma samples, a 399 
positive control (plasma from participant COV727,8, diluted 66.6-fold and with seven additional 400 
threefold serial dilutions in PBS) was added to every assay plate for validation. The average of 401 
its signal was used for normalization of all of the other values on the same plate with Excel 402 
software before calculating the area under the curve using Prism V8.4 (GraphPad). For 403 
monoclonal antibodies, the EC50 was determined using four-parameter nonlinear regression 404 
(GraphPad Prism V8.4).  405 
 406 
Expression of RBD proteins  407 
Mammalian expression vectors encoding the RBDs of SARS-CoV-2 (GenBank MN985325.1; S 408 
protein residues 319-539) and eight additional mutant RBD proteins (E484K, Q493R, R346S, 409 
N493K, N440K, V367F, A475V, S477N and V483A) with an N-terminal human IL-2 or Mu 410 
phosphatase signal peptide were previously described30.  411 
 412 
Cells and viruses 413 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted January 30, 2021. ; https://doi.org/10.1101/2021.01.15.426911doi: bioRxiv preprint 
 21 
293TAce2 8, 293T/ACE2.cl22 and HT1080/ACE2.cl14 cells10 were cultured in Dulbecco’s 414 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37oC 415 
and 5% CO2. Cells were periodically tested for contamination with mycoplasma or retroviruses.  416 
rVSV/SARS-CoV-2/GFP chimeric virus stocks were generated by infecting 293T/ACE2.cl22 417 
cells. Supernatant was harvested 1 day post infection (dpi), cleared of cellular debris, and stored 418 
at -80oC. A plaque purified variant designated rVSV/SARS-CoV-2/GFP2E1 that encodes 419 
D215G/R683G substitutions was used in these studies10. 420 
 421 
Selection and analysis of antibody escape mutations 422 
For the selection of monoclonal antibody-resistant spike variants, an rVSV/SARS-CoV-2/GFP2E1 423 
(for details see10) population containing 106 infectious units was incubated with monoclonal 424 
antibodies at 10-40 μg/ml for 1 hr at 37 °C. The virus-antibody mixtures were subsequently 425 
incubated with 5× 105 293T/ACE2cl.22 cells in 6-well plates. One day after infection the media 426 
was replaced with fresh media containing the equivalent concentration of antibodies. Supernatant 427 
was harvested 2 days after infection and 150 μl of the cleared supernatant was used to infect cells 428 
for passage 2, while 150 μl was subjected to RNA extraction and sequencing.  429 
For identification of putative antibody resistance mutations, RNA was extracted using 430 
NucleoSpin 96 Virus Core Kit (Macherey-Nagel). The RNA was reversed transcribed using the 431 
SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). KOD Xtreme Hot Start DNA 432 
Polymerase (Millipore Sigma) was used for amplification of cDNA using primers flanking the S-433 
encoding sequence. The PCR products were purified and sequenced as previously described7,12. 434 
Briefly, tagmentation reactions were performed using 1ul diluted cDNA, 0.25 µl Nextera TDE1 435 
Tagment DNA enzyme (catalog no. 15027865), and 1.25 µl TD Tagment DNA buffer (catalog 436 
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no. 15027866; Illumina). Next, the DNA was ligated to unique i5/i7 barcoded primer 437 
combinations using the Illumina Nextera XT Index Kit v2 and KAPA HiFi HotStart ReadyMix 438 
(2X; KAPA Biosystems) and purified using AmPure Beads XP (Agencourt), after which the 439 
samples were pooled into one library and subjected to paired-end sequencing using Illumina 440 
MiSeq Nano 300 V2 cycle kits (Illumina) at a concentration of 12pM. 441 
For analysis of the sequencing data, the raw paired-end reads were pre-processed to remove trim 442 
adapter sequences and to remove low-quality reads (Phred quality score < 20) using BBDuk. 443 
Reads were mapped to the rVSV/SARS-CoV-2/GFP sequence using Geneious Prime (Version 444 
2020.1.2). Mutations were annotated using Geneious Prime, with a P-value cutoff of 445 
10−6.  Because reads have randomly generated ends and different lengths, the mutations do not 446 
necessarily have to occur on the same read. e.g K417N and N501Y might occur on the same read 447 
or on different reads. The percentages calculated for position X are calculated based on all the 448 
reads, and not just the reads, that include position X.  449 
 450 
SARS-CoV-2 pseudotyped reporter virus  451 
A panel of plasmids expressing RBD-mutant SARS-CoV-2 spike proteins in the context of 452 
pSARS-CoV-2-S Δ19 (based on (NC_045512)) have been described previously12. Additional 453 
substitutions were introduced using either PCR primer-mediated mutagenesis or with synthetic 454 
gene fragments (IDT) followed by Gibson assembly. The mutants E484K and KEN 455 
(K417N+E484K+N501Y) were constructed in the context of a pSARS-CoV-2-S Δ19 variant with 456 
a mutation in the furin cleavage site (R683G). The NT50s and IC50 of these pseudotypes were 457 
compared to a wildtype SARS-CoV-2 spike sequence carrying R683G in the subsequent 458 
analyses, as appropriate. 459 
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Generation of SARS-CoV-2 pseudotyped HIV-1 particles was performed as previously 460 
described8. Briefly, 293T cells were transfected with pNL4-3DEnv-nanoluc and pSARS-CoV-2-461 
SΔ19 and pseudotyped virus stocks were harvested 48 hours after transfection, filtered and stored 462 
at -80℃. 463 
 464 
SARS-CoV-2 pseudotype neutralization assays 465 
Plasma or monoclonal antibodies from vaccine recipients were four-fold or five-fold serially 466 
diluted and then incubated with SARS-CoV-2 pseudotyped HIV-1 reporter virus for 1 h at 37 °C. 467 
The antibody and pseudotyped virus mixture was added to 293TAce2 cells8 (for comparisons of 468 
plasma or monoclonal antibodies from COVID-19-convalescents and vaccine recipients) or 469 
HT1080ACE2.cl14 cells10 (for analysis of spike mutants with vaccine recipient plasma or 470 
monoclonal antibodies). After 48 h cells were washed with PBS and lysed with Luciferase Cell 471 
Culture Lysis 5× reagent (Promega) and Nanoluc Luciferase activity in lysates was measured 472 
using the Nano-Glo Luciferase Assay System (Promega) with the Glomax Navigator (Promega). 473 
The relative luminescence units were normalized to those derived from cells infected with 474 
SARS-CoV-2 pseudotyped virus in the absence of plasma or monoclonal antibodies. The half-475 
maximal and 80% or 90% neutralization titers for plasma (NT50 and NT80/NT90, respectively) or 476 
half-maximal and 90% inhibitory concentrations for monoclonal antibodies (IC50 and IC90, 477 
respectively) were determined using four-parameter nonlinear regression (least squares 478 
regression method without weighting; constraints: top=1, bottom=0) (GraphPad Prism). 479 
 480 
Biotinylation of viral protein for use in flow cytometry 481 
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Purified and Avi-tagged SARS-CoV-2 RBD was biotinylated using the Biotin-Protein Ligase-482 
BIRA kit according to manufacturer’s instructions (Avidity) as described before8. Ovalbumin 483 
(Sigma, A5503-1G) was biotinylated using the EZ-Link Sulfo-NHS-LC-Biotinylation kit 484 
according to the manufacturer’s instructions (Thermo Scientific). Biotinylated ovalbumin was 485 
conjugated to streptavidin-BV711 (BD biosciences, 563262) and RBD to streptavidin-PE (BD 486 
Biosciences, 554061) and streptavidin-AF647 (Biolegend, 405237)8. 487 
 488 
Flow cytometry and single cell sorting 489 
Single-cell sorting by flow cytometry was performed as described previously8. Briefly, 490 
peripheral blood mononuclear cells were enriched for B cells by negative selection using a pan-491 
B-cell isolation kit according to the manufacturer’s instructions (Miltenyi Biotec, 130-101-638). 492 
The enriched B cells were incubated in FACS buffer (1× PBS, 2% FCS, 1 mM EDTA) with the 493 
following anti-human antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 494 
335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41), anti-CD8-APC-eFluor 780 495 
(Invitrogen, 47-0086-42), anti-CD16-APC-eFluor 780 (Invitrogen, 47-0168-41), anti-CD14-496 
APC-eFluor 780 (Invitrogen, 47-0149-42), as well as Zombie NIR (BioLegend, 423105) and 497 
fluorophore-labelled RBD and ovalbumin (Ova) for 30 min on ice. Single 498 
CD3−CD8−CD14−CD16−CD20+Ova−RBD-PE+RBD-AF647+ B cells were sorted into 499 
individual wells of 96-well plates containing 4 μl of lysis buffer (0.5× PBS, 10 mM DTT, 3,000 500 
units/ml RNasin Ribonuclease Inhibitors (Promega, N2615) per well using a FACS Aria III and 501 
FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis. The sorted cells 502 
were frozen on dry ice, and then stored at −80 °C or immediately used for subsequent RNA 503 
reverse transcription.  504 
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 505 
Antibody sequencing, cloning and expression 506 
Antibodies were identified and sequenced as described previously8. In brief, RNA from single 507 
cells was reverse-transcribed (SuperScript III Reverse Transcriptase, Invitrogen, 18080-044) and 508 
the cDNA stored at −20 °C or used for subsequent amplification of the variable IGH, IGL and 509 
IGK genes by nested PCR and Sanger sequencing. Sequence analysis was performed using 510 
MacVector. Amplicons from the first PCR reaction were used as templates for sequence- and 511 
ligation-independent cloning into antibody expression vectors. Recombinant monoclonal 512 
antibodies and Fabs were produced and purified as previously described8. 513 
 514 
Cryo-EM sample preparation 515 
Expression and purification of SARS-CoV-2 6P stabilized S trimers37  was conducted as 516 
previously described53. Purified Fab and S 6P trimer were incubated at a 1.1:1 molar ratio per 517 
protomer on ice for 30 minutes prior to deposition on a freshly glow-discharged 300 mesh, 518 
1.2/1.3 Quantifoil copper grid. Immediately before 3 µl of complex was applied to the grid, 519 
fluorinated octyl-malotiside was added to the Fab-S complex to a final detergent concentration of 520 
0.02% w/v, resulting in a final complex concentration of 3 mg/ml. Samples were vitrified in 521 
100% liquid ethane using a Mark IV Vitrobot after blotting for 3 s with Whatman No. 1 filter 522 
paper at 22˚C and 100% humidity. 523 
 524 
Cryo-EM data collection and processing 525 
Data collection and processing followed a similar workflow to what has been previously 526 
described in detail29. Briefly, micrographs were collected on a Talos Arctica transmission 527 
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electron microscope (Thermo Fisher) operating at 200 kV for all Fab-S complexes. Data were 528 
collected using SerialEM automated data collection software54 and movies were recorded with a 529 
K3 camera (Gatan). For all datasets, cryo-EM movies were patch motion corrected for beam-530 
induced motion including dose-weighting within cryoSPARC v2.1555 after binning super 531 
resolution movies. The non-dose-weighted images were used to estimate CTF parameters using 532 
cryoSPARC implementation of the Patch CTF job. Particles were picked using Blob picker and 533 
extracted 4x binned and 2D classified. Class averages corresponding to distinct views with 534 
secondary structure features were chosen and ab initio models were generated. 3D classes that 535 
showed features of a Fab-S complex were re-extracted, unbinned (0.869 Å/pixel) and 536 
homogenously refined with C1 symmetry. Overall resolutions were reported based on gold 537 
standard FSC calculations. 538 
 539 
Cryo-EM Structure Modeling and Refinement 540 
Coordinates for initial complexes were generated by docking individual chains from reference 541 
structures into cryo-EM density using UCSF Chimera56 (S trimer: PDB 6KXL, Fab: PDB 6XCA 542 
or 7K8P after trimming CDR3 loops and converting to a polyalanine model). Models were then 543 
refined into cryo-EM maps by rigid body and real space refinement in Phenix57. If the resolution 544 
allowed, partial CDR3 loops were built manually in Coot58 and then refined using real-space 545 
refinement in Phenix.  546 
 547 
Computational analyses of antibody sequences 548 
Antibody sequences were trimmed based on quality and annotated using Igblastn v.1.14. with 549 
IMGT domain delineation system. Annotation was performed systematically using Change-O 550 
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toolkit v.0.4.540 59. Heavy and light chains derived from the same cell were paired, and 551 
clonotypes were assigned based on their V and J genes using in-house R and Perl scripts (Fig. 2c 552 
and f, Extended data Fig. 3d, Extended data Fig. 4b). All scripts and the data used to process 553 
antibody sequences are publicly available on GitHub (https://github.com/stratust/igpipeline). 554 
 555 
The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study 556 
was compared to 131,284,220 IgH and IgL sequences generated by 60 and downloaded from 557 
cAb-Rep 61, a database of human shared BCR clonotypes available at https://cab-558 
rep.c2b2.columbia.edu/. Based on the 97 distinct V genes that make up the 4186 analyzed 559 
sequences from Ig repertoire of the 14 participants present in this study, we selected the IgH and 560 
IgL sequences from the database that are partially coded by the same V genes and counted them 561 
according to the constant region. The frequencies shown in (Fig 2e and Extended Data Fig 4a) 562 
are relative to the source and isotype analyzed. We used the two-sided binomial test to check 563 
whether the number of sequences belonging to a specific IgHV or IgLV gene in the repertoire is 564 
different according to the frequency of the same IgV gene in the database. Adjusted p-values 565 
were calculated using the false discovery rate (FDR) correction. Significant differences are 566 
denoted with stars. 567 
 568 
Nucleotide somatic hypermutation and CDR3 length were determined using in-house R and Perl 569 
scripts. For somatic hypermutations, IGHV and IGLV nucleotide sequences were aligned against 570 
their closest germlines using Igblastn and the number of differences were considered nucleotide 571 
mutations. The average mutations for V genes were calculated by dividing the sum of all 572 
nucleotide mutations across all participants by the number of sequences used for the analysis. To 573 
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calculate the GRAVY scores of hydrophobicity62  we used Guy H.R. Hydrophobicity scale based 574 
on free energy of transfer (kcal/mole)63 implemented by the R package Peptides (the 575 
Comprehensive R Archive Network repository; https://journal.r-project.org/archive/2015/RJ-576 
2015-001/RJ-2015-001.pdf). We used 1405 heavy chain CDR3 amino acid sequences from this 577 
study and 22,654,256 IGH CDR3 sequences from the public database of memory B cell receptor 578 
sequences64. The two-tailed Wilcoxon nonparametric test was used to test whether there is a 579 
difference in hydrophobicity distribution. 580 
 581 
Data availability statement: Data are provided in Extended Data Tables 1-7. The raw 582 
sequencing data and computer scripts associated with Fig. 2 have been deposited at Github 583 
(https://github.com/stratust/igpipeline). This study also uses data from “A Public Database of 584 
Memory and Naive B-Cell Receptor Sequences” 64, PDB (6VYB and 6NB6) and from “High 585 
frequency of shared clonotypes in human B cell receptor repertoires” 60. Cryo-EM maps 586 
associated with data reported in this manuscript will be deposited in the Electron Microscopy 587 
Data Bank (EMDB: https://www.ebi.ac.uk/pdbe/emdb/) under accession codes EMD-23393 588 
(C601-S), EMD-23394 (C603-S), EMD-23395 (C643-S), EMD-23396 (C663-S), EMD-23397 589 
(C666-S), EMD-23398 (C669-S), and EMD-23399 (C670-S).  590 
 591 
Data presentation 592 
Figures were arranged in Adobe Illustrator 2020. 593 
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Code availability statement: Computer code to process the antibody sequences is available at 598 
GitHub (https://github.com/stratust/igpipeline). 599 
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Extended Data Fig. 1. Plasma antibodies against SARS-CoV-2.  a–f, Results of ELISAs 628 
measuring plasma reactivity to S (a,c,e) and RBD protein (b,d,f) of 20 vaccinees (grey curves) 629 
and 8 controls (black curves). a, Anti-S IgG. b, Anti-RBD IgG. c, Anti-S IgM. d, Anti-RBD 630 
IgM. e, Anti-S IgA. f, Anti-RBD IgA. Left, optical density at 450 nm (OD 450 nm) for the 631 
indicated reciprocal plasma dilutions. Right, normalized area under the curve (AUC) values for 632 
the 8 controls and 20 vaccinees. Horizontal bars indicate geometric mean. Statistical significance 633 
was determined using the two-tailed Mann–Whitney U-test. Average of two or more 634 
experiments. g-i, Correlations of plasma antibodies measurements. g, Normalized AUC for IgG 635 
anti-S (X axis) plotted against normalized AUC for IgG anti-RBD (Y axis). h, Normalized AUC 636 
for IgM anti-S (X axis) plotted against normalized AUC for IgM anti-RBD (Y axis). i, 637 
Normalized AUC for IgA anti-S (X axis) plotted against normalized AUC for IgA anti-RBD (Y 638 
axis). The r and p values in g-i were determined with the two-tailed Spearman’s correlation test. 639 
Moderna vaccinees are in black and Pfizer-BioNTech in red. j-l, Results of ELISAs measuring 640 
plasma reactivity to RBD in convalescent volunteers 1.3 and 6.2 months after infection7,8 and in 641 
20 vaccinees, who received the Moderna vaccine (black dots) and Pfizer-BioNTech vaccine (red 642 
dots). j, Anti-RBD IgG. k, Anti-RBD IgM. l, Anti-RBD IgA. The normalized area under the 643 
curve (AUC) values are shown. Positive and negative controls were included for validation. Red 644 
horizontal bars and indicated values represent geometric mean. Statistical significance was 645 
determined using two-tailed Mann–Whitney U-test or Wilcoxon matched-pairs signed rank test. 646 
   647 
Extended Data Fig. 2: Plasma neutralizing activity. a, Anti-S IgM AUC (Y axis) plotted 648 
against NT50 (X axis) r=0.12, p<0.62. b, Anti-S IgA AUC (Y axis) plotted against NT50 (X axis) 649 
r=0.79, p<0.0001. c, Anti-RBD IgM AUC (Y axis) plotted against NT50 (X axis) r=-0.079 650 
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p=0.74. d, Anti-RBD IgA AUC (Y axis) plotted against NT50 (X axis) r=0.69 p=0.0008. e, NT50 651 
(Y axis) plotted against time between last dose and blood draw (X axis) r=-0.63 p=0.0032. f, 652 
NT50 (Y axis) plotted against time between doses (X axis) r=0.03 p=0.89. g, Anti-RBD IgG AUC 653 
(Y axis) plotted against time between last dose and blood draw (X axis) r=-0.57 p=0.0084. h, 654 
Anti-S IgG AUC (Y axis) plotted against time between last dose and blood draw (X axis) r=-0.59 655 
p=0.0064. i, Age (Y axis) plotted against NT50 (X axis) r=-0.06 p=0.82. The r and p values were 656 
determined by two-tailed Spearman’s. Moderna vaccinees in black and Pfizer-BioNTech in red. 657 
j, NT50 values for vaccinee plasma (n=15) neutralization of pseudotyped viruses with WT and 658 
the indicated RBD-mutant SARS-CoV-2 S proteins; p-values determined using one tailed t-test. 659 
 660 
Extended Data Fig. 3: Flow cytometry. a, Gating strategy used for cell sorting. Gating was on 661 
singlets that were CD20+ and CD3-CD8-CD14-CD16-OVA-. Sorted cells were RBD-PE+ and 662 
RBD-AF647+. b, Flow cytometry showing the percentage of RBD-double positive memory B 663 
cells from a pre-COVID-19 control (HD) and 15 vaccinees, who received the Moderna vaccine 664 
are shown in black and Pfizer-BioNTech vaccine recipients are in red. c, the percentage of RBD-665 
binding memory B cells in vaccinees (Y axis) plotted against time between first dose and blood 666 
draw (X axis) r=0.40 p=0.087 (left panel), and between last dose and blood draw (X axis) r=0.33 667 
p=0.17 (right panel). Moderna vaccinees in black and Pfizer-BioNTech in red. The r and p values 668 
for correlations were determined by two-tailed Spearman’s. d, Pie charts show the distribution of 669 
antibody sequences from 10 individuals in b. The number in the inner circle indicates the number 670 
of sequences analyzed. Pie slice size is proportional to the number of clonally related sequences. 671 
The black outline indicates the frequency of clonally expanded sequences. The r and p values for 672 
correlations in c were determined by the two-tailed Spearman correlation test. 673 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted January 30, 2021. ; https://doi.org/10.1101/2021.01.15.426911doi: bioRxiv preprint 
 33 
 674 
Extended Data Fig. 4: Frequency distributions of human VL genes.  675 
Graph shows relative abundance of human IGVK (left) and IgVL (right) genes of Sequence Read 676 
Archive accession SRP010970 (orange)65, and vaccinees (blue). Two-sided binomial tests with 677 
unequal variance were used to compare the frequency distributions., significant differences are 678 
denoted with stars (* p < 0.05, ** p < 0.01, *** p < 0.001, **** = p < 0.0001). b. Sequences 679 
from 14 individuals (Extended Data Table 3) with clonal relationships. Interconnecting lines 680 
indicate the relationship between antibodies that share V and J gene segment sequences at both 681 
IGH and IGL. Purple, green and grey lines connect related clones, clones and singles, and singles 682 
to each other, respectively.  683 
 684 
Extended Data Fig. 5: Antibody somatic hypermutation, and CDR3 length. a, Number of 685 
somatic nucleotide mutations in both the IGVH and IGVL in 14 participants (left). Individuals 686 
who received the Moderna vaccine are shown in black and Pfizer-BioNTech vaccine recipients 687 
in red. For each individual, the number of the amino acid length of the CDR3s at the IGVH and 688 
IGVL is shown (right). The horizontal bars indicate the mean. The number of antibody 689 
sequences (IGVH and IGVL) evaluated for each participant are n=68 (MOD1), n=45 (MOD2), 690 
n=117 (MOD3), n=123 (MOD4), n=110 (MOD6), n=109 (MOD7), n=144 (MOD8), n=102 691 
(MOD9), n=132 (PFZ10), n=109 (MOD11), n=91 (PFZ12), n=78 (C001), n=66 (C003), and 692 
n=115 (C004). b, Distribution of the hydrophobicity GRAVY scores at the IGH CDR3 compared 693 
to a public database (see Methods for statistical analysis). The box limits are at the lower and 694 
upper quartiles, the center line indicates the median, the whiskers are 1.5× interquartile range and 695 
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the dots represent outliers. Statistical significance was determined using two-tailed Wilcoxon 696 
matched-pairs signed rank test (**** = p < 0.0001). 697 
 698 
Extended Data Fig. 6: Monoclonal antibody ELISAs. a, Graphs show anti-SARS-CoV-2 699 
RBD antibody reactivity. ELISA EC50 values for all antibodies isolated from COVID-19 700 
convalescent individuals assayed at 1.3 and 6.2 months after infection7,8 and 127 selected 701 
monoclonal antibodies isolated from 4 Moderna vaccinees (black dots) and 4 Pfizer-BioNTech 702 
vaccinees (red dots) measured at 8 weeks after the boost. Red horizontal bars and indicated 703 
values represent geometric mean. Statistical significance was determined using two-tailed 704 
Mann–Whitney U-test. b-c, Graphs show ELISA titration curves for 86 monoclonal antibodies 705 
isolated from Moderna vaccinees (b) and 41 monoclonal antibodies isolated from Pfizer-706 
BioNTech vaccinees (c). d-l, Graphs show ELISA titrations for 84 antibodies isolated from 707 
Moderna vaccinees against the indicated RBD variants.  Isotype control and low-binding 708 
antibodies are indicated in colors. C661 is a non-binding antibody. Data are representative of two 709 
independent experiments. m, Relative change in EC50 values for the indicated RBD variants 710 
over wt RBD of 84 antibodies isolated from Moderna vaccinees. Red horizontal bars represent 711 
geometric mean. n, a heat map summary of EC50 values for binding to wild type RBD and the 712 
indicated mutant RBDs for 17 top neutralizing antibodies.  713 
 714 
Extended Data Fig. 7: Neutralizing activity of monoclonal antibodies in clinical 715 
development against SARS-CoV-2 variants. a, Results of a SARS-CoV-2 pseudovirus 716 
neutralization assay. IC50 values for 6 different monoclonal antibodies, alone or in their clinically 717 
designated combinations, for neutralization of wild type and the indicated mutant SARS-CoV-2 718 
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pseudotyped viruses. Antibodies with IC50 values above 1000 ng/ml were plotted at 1000 ng/ml. 719 
Data are the mean of 2 independent experiments. Color gradient indicates IC50 values ranging 720 
from 0 (white) to 1000 ng/ml (red). The combination of REGN 10987 and 10933 (casirivimab 721 
and imdevimab, respectively)13,66,67 has been granted emergency use authorization by the U.S. 722 
FDA, the combination of COV2-2196 and COV2-2130 (licensed to Astra Zeneca as 723 
AZD7442)26, and the combination of C135 and C144 (The Rockefeller University)8 are currently 724 
in clinical trials (NCT04507256 and NCT04700163, respectively).      725 
 726 
Extended Data Fig. 8: Local resolution estimates of Fab-S cryo-EM reconstructions. a-g, 727 
Local resolution maps calculated using cryoSPARC for (a) C669-S, (b) C643-S, (c) C603-S, (d) 728 
C601-S, (e) C666-S, (f) C663-S, and (g) C670-S complexes. Close-up views for Fab-RBD 729 
interfaces are highlighted for (a) C669 and (b) C643. h, Gold-standard Fourier shell correlation 730 
curves for Fab-S complexes. The 0.5 and 0.143 cutoffs are indicated by dashed lines. 731 
  732 
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 733 
Supplementary Guide 734 
Supplementary Table 1: Individual vaccinee characteristics  735 
Supplementary Table 2: Neutralization of WT/KEN pseudovirus by convalescent plasma 736 
Supplementary Table 3: Antibody sequences from vaccinees is provided as a separate Excel 737 
file 738 
Supplementary Table 4: CDR3 alignment of highly identical clonal sequences 739 
Supplementary Table 5: Sequences, half maximal effective concentrations (EC50s) and 740 
inhibitory concentrations (IC50s) of the cloned monoclonal antibodies is provided as a 741 
separate Excel file 742 
Supplementary Table 6: Neutralization activity of mAbs against mutant SARS-CoV-2 743 
pseudoviruses 744 
Supplementary Table 7: Cryo-EM data collection and processing statistics 745 
 746 
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C682 45 29 26 1000 23 43 12 1000 62 110 214 383 28
C613 20 16 12 273 45 22 47 1000 33 30 236 1000 13
C663 11 8 8 80 19 14 14 382 17 32 60 1000 12
C614 5 4 4 1000 4 6 5 32 4 9 7 16 4
C660 6 4 5 413 9 8 5 8 5 11 8 17 5
Class 1/2 C653 10 7 7 1000 8 9 19 20 10 1000 168 34 8
C627 5 3 4 7 3 5 4 4 3 1000 1000 18 4
C602 14 10 8 5 16 16 13 11 13 1000 58 82 10
C671 5 3 6 5 5 7 6 6 5 1000 283 28 5
C643 2 1 1 2 2 2 1 2 2 1000 1 6 2
C603 14 7 209 5 12 13 12 19 11 1000 7 56 11
C628 19 12 9 5 257 30 36 16 18 1000 147 1000 14
C669 15 17 9 12 1000 1000 20 13 14 24 13 141 17
C670 14 12 10 8 1000 16 17 12 11 50 15 1000 13
C666 4 2 4 2 3 4 3 7 3 240 4 10 4
C601 2 1 2 1 2 2 1 2 2 112 3 5 2















































































Class 1/2 C653 90 13
C627 37 27





C669 13 21 23 26 15
C670 17 16 23 41
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S vs. RBD IgG
r = 0.98
P < 0.0001
















S vs. RBD IgM
r = 0.88
P < 0.0001
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C682 2.4 2.2 2.6 3.6 3.5 35.0 3.3 2.8 3.7 4.1
C613 2.0 1.9 1.8 3.3 2.5 126.1 2.4 2.3 2.2 4.9
C663 1.9 1.8 1.7 2.7 2.5 12.6 2.3 2.0 2.4 2.2
C614 1.4 1.6 1.6 2.0 1.9 2.5 1.8 1.9 1.6 1.8
C660 2.0 2.0 2.1 2.3 2.7 2.5 2.1 2.2 2.4 2.2
Class 1/2 C653 2.1 2.1 2.1 2.5 2.6 2.2 2.1 2.3 4.0 3.1
C627 1.6 1.6 1.8 2.0 2.0 2.1 1.9 1.8 1000 1000
C602 2.0 1.8 1.9 2.1 2.2 2.2 2.1 3.1 1000 1.9
C671 2.3 1.7 1.5 2.4 2.4 2.5 2.0 1.8 1000 2.5
C643 2.1 2.2 2.3 2.0 2.2 1.7 1.8 2.5 1000 1.9
C603 2.1 1.7 1.7 2.1 2.2 2.3 2.0 1.9 1000 1.9
C628 2.7 1.9 2.0 4.3 3.2 3.1 2.4 2.4 10.0 3.2
C669 2.3 2.1 2.2 950.6 291.8 2.1 2.1 2.2 2.4 2.2
C670 2.9 2.1 2.3 210.7 2.8 3.0 2.6 2.4 3.3 3.3
C666 1.9 1.7 1.8 2.0 2.1 1.5 1.8 1.9 2.1 1.8
C601 1.1 1.8 2.1 2.2 2.2 1.9 1.9 2.2 12.1 2.0
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REG10987 8 10 2 765 6 7 2
REG10933 3 4 17 3 3 36 527
10987+10933 4 6 3 6 3 9 4
COV2-2196 3 4 1 2 3 44 16
COV2-2130 3 5 2 4 3 4 3
2196+2130 3 5 1 3 2 7 4
C135 10 18 3 1000 14 7 3
C144 2 4 1 2 3 1000 1000
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